ArticlePharmaceuticals (Basel, Switzerland)2023

Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience.

Vlasta Oršić Frič et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.